FILTER
FILTERED INTERVIEW RESULTS
Alfredo Ison
EXECUTIVE PRESIDENT, QUÍMICA DELTA
Química Delta explains how it continues to grow its share of Mexico’s chemical distribution market.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
"The company is expanding its footprint in Latin America and opened a new office in Peru in February."
Martín Toscano
PRESIDENT, EVONIK INDUSTRIES MEXICO
"We need a strong, robust, competitive and sustainable chemical industry in Mexico to capitalize on this regionalization and advantages such as the United States-Mexico-Canada Agreement (USMCA)."
Miguel Benedetto
DIRECTOR GENERAL, CHEMICAL INDUSTRY ASSOCIATION OF MEXICO (ANIQ)
"The industry is willing to economically support Pemex to further invest in infrastructure to increase the supply of raw materials."
Sergio Aburto
LATIN AMERICA NORTH DIRECTOR, ACADIAN PLANT HEALTH
Acadian Plant Health explains how its crop care products based on seaweed can benefit Mexico’s farmers.
Verónica Pérez
PRESIDENT – NORTH REGION OF LATIN AMERICA, THE DOW CHEMICAL COMPANY
The Dow Chemical Company speaks to GBR about its Mexican opertaions.
Rafael Méndez
REGIONAL DIRECTOR – LATAM NORTHERN TIER, CRODA
Croda explains how it adapts its products according to the trends and changes of the Mexican market.
Gerardo Berea Montes
SPECIAL GASES DIRECTOR, GRUPO INFRA
Grupo Infra speaks to GBR about opportunities in special gases in Mexico.
Miguel Valdivia
COMMERCIAL DIRECTOR, TRADE CHEMICALS & PRODUCTS
Trade Chemicals & Products explains how it has continued supplying its customers in Mexico with the chemical products that they need despite shortages and price increases.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
